Tau Pipeline Enabling Program V (T-PEP)
Forecasted
The Tau Pipeline Enabling Program V (T-PEP) from the Alzheimer's Association funds translational research to advance tau-targeted therapies for neurodegenerative diseases toward clinical application.
Funder: Alzheimer's Association
Due Dates (Anticipated): May 2027 (Letter of Intent) | August 2027 (Full Application)
Funding Amounts: Up to $750,000 total over 2 years; nonprofits may request up to 10% indirect costs, for-profits not eligible for indirect costs.
Summary: Supports translational research to advance therapies for tauopathies, moving academic innovations toward clinical application.
Key Information: Letter of Intent is required; only invited applicants may submit a full proposal.
Description
The Tau Pipeline Enabling Program V (T-PEP) is designed to accelerate the development of new therapies for tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The program specifically funds translational, milestone-driven projects that advance candidate therapies through critical stages such as development candidate selection, lead optimization, in vivo proof-of-concept, and IND-enabling studies focused on tau or tau-related mechanisms. T-PEP is intended to bridge the gap between academic innovation and the resources of larger pharmaceutical companies, promoting the advancement of disease-modifying interventions for tauopathies.
